As regulated companies, medical device firms must stay abreast of the latest developments to ensure they adopt new protocols to maintain quality assurance.
Telemedicine has thrived during COVID-19 but its post-pandemic momentum will depend on regulatory changes, connectivity parity, and improved interoperability.
The “year of evaluating everything” represents a significant opportunity to modernize clinical research.
Online ExclusivesSeth J. Goldenberg, Ph.D., Vice President, Vault Medical Device & Diagnostics; Kevin Liang, Ph.D., Sr. Director, Strategy, Medical Device and Diagnostics, Veeva Systems11.18.20